sarcoma

This page shows the latest sarcoma news and features for those working in and with pharma, biotech and healthcare.

Nanobiotix signs €40m deal with the EIB

The candidate just hit its primary endpoint in a Phase II/III trial in soft tissue sarcoma (STS).

AstraZeneca expands alliance with Bicycle Therapeutics

The peptide portion of BT1718 binds to MT1-MMP, which is highly expressed in many solid tumours, including triple negative breast cancer, sarcoma and non-small cell lung cancer, and is
Merck forges closer ties with Cancer Research UK

notable pipeline failures, including evofosfamide for advanced soft tissue sarcoma and pancreatic cancer.
Bayer gets clinical data to support $1.5bn Loxo deal

uncontrolled cellular growth that is evident in a wide range of tumours, including infantile fibrosarcoma, thyroid cancer and various soft tissue sarcomas, but collectively account for less than 1% of all
Loxo’s cancer drug pair attracts $1.5bn deal with Bayer

They are seen in a collection of malignancies including colorectal adenocarcinoma, soft tissue sarcoma, infantile fibrosarcoma and cholangiocarcinoma.
Avelumab costs peg back profit at Merck KGaA

sarcoma and pancreatic cancer after phase III study failures.

More from news
Approximately 6 fully matching, plus 49 partially matching documents found.

Europe vs the US: New drug product approvals

Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),
Case study: Treatment guidance

The Practical Guide was launched as part of a Takeda sponsored symposium at the British Sarcoma Group’ s annual conference.
Case study: Treatment guidance

The Practical Guide was launched as part of a Takeda sponsored symposium at the British Sarcoma Group’ s annual conference.
Pharma deals during February 2014

for advanced sarcoma.
Interview: Harvey Berger and Timothy Clackson, Ariad

And that was absolutely correct.”. After selling off investigational sarcoma treatment ridaforolimus to Merck &Co following an aborted collaboration attempt, ponatinib emerged as the front-runner in the company's pipeline

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Add my company

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...